

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DAGGETT *et al.*
Serial No. 08/935,105
Filed: September 29, 1997
For: HUMAN N-METHYL-D-ASPARTATE
RECEPTOR SUBUNITS, NUCLEIC
ACIDS ENCODING SAME AND
USES THEREFOR
Art Unit: 1646
Examiner: Ulm, J.

I hereby certify that this paper and the attached
papers are being deposited with the United
States Postal Service as first class mail in an
envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

Date

2-19-98 Nancy V. McElrath
Nancy V. McElrath

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed after receipt of a First Office Action on the Merits for the above-captioned application, the filing fee of \$240.00 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 02-4070.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited documents are provided herewith. All the documents or abstracts listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R.



U.S.S.N. 08/935,105
DAGGETT, *et al.*
SUPPLEMENTAL IDS

§1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and that they be made of record in the file history of the above-captioned application.

* * *

Respectfully submitted,
BROWN, MARTIN, HALLER & McCLAIN

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 6362-9383D
Address all correspondence to:
BROWN, MARTIN, HALLER & McCLAIN
1660 Union Street
San Diego, California 92101-2926
Telephone: (619) 238-0999
EMAIL sseidman@BMHM.com

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 6362-9383D	SERIAL NO. 08/935,105
	APPLICANT DAGGETT <i>et al.</i>	
	FILING DATE September 29, 1997	GROUP 1646

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	A	Sun <i>et al.</i> , Molecular cloning, chromosomal mapping, and functional expression of human brain glutamate receptors, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:1443-1447 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.